The development and characterization of H5 influenza virus vaccines derived from a 2003 human isolate
Abstract
No abstract availableKeywords
Funding Information
- Japan Science and Technology Corporation
- Ministry of Education, Culture, Sports, Science and Technology
- National Institute of Allergy and Infectious Diseases
- U.S. Public Health Service
- Core Research for Evolutional Science and Technology
This publication has 30 references indexed in Scilit:
- Generation of reassortant influenza vaccines by reverse genetics that allows utilization of a DIVA (Differentiating Infected from Vaccinated Animals) strategy for the control of avian influenzaVaccine, 2004
- Genesis of a highly pathogenic and potentially pandemic H5N1 influenza virus in eastern AsiaNature, 2004
- Are We Ready for Pandemic Influenza?Science, 2003
- Exploitation of Nucleic Acid Packaging Signals To Generate a Novel Influenza Virus-Based Vector Stably Expressing Two Foreign GenesJournal of Virology, 2003
- International Standards for the Control of Avian InfluenzaAvian Diseases, 2003
- Safety and antigenicity of non-adjuvanted and MF59-adjuvanted influenza A/Duck/Singapore/97 (H5N3) vaccine: a randomised trial of two potential vaccines against H5N1 influenzaThe Lancet, 2001
- Generation of a Highly Pathogenic Avian Influenza A Virus from an Avirulent Field Isolate by Passaging in ChickensJournal of Virology, 2001
- Pandemic Threat Posed by Avian Influenza A VirusesClinical Microbiology Reviews, 2001
- Recombinant Influenza A Virus Vaccines for the Pathogenic Human A/Hong Kong/97 (H5N1) VirusesThe Journal of Infectious Diseases, 1999
- Characterization of an Avian Influenza A (H5N1) Virus Isolated from a Child with a Fatal Respiratory IllnessScience, 1998